Scholarlink

Background <p>This study investigates the effects of carbamazepine (CBZ) carbon nanodot functionalized silver nanoparticles (CBZ-CD@AgNP) and carbamazepine-loaded metal–organic frameworks (CBZ-CDs@MOFs) on the brain of male rats in an epilepsy model.</p> Methods <p>In our study, 70 male Wistar albino rats aged 8–12&#xa0;weeks were used. Experimental groups Control group, PTZ (Pentylenetetrazole) group, Carbamazepine 25&#xa0;mg/kg group, Carbamazepine 50&#xa0;mg/kg group, PTZ + Carbamazepine 25&#xa0;mg/kg group, PTZ + Carbamazepine 50&#xa0;mg/kg group, Carbamazepine 25&#xa0;mg/kg + MOF group, Carbamazepine 50&#xa0;mg/kg group + MOF group, PTZ + Carbamazepine 25&#xa0;mg/kg group + MOF group, PTZ + Carbamazepine 50&#xa0;mg/kg group + MOF group.</p> Results <p>Immunohistochemical analysis showed an increase in GRP78 expression in all CBZ-nanoparticle groups, indicating a protective effect. However, 25&#xa0;mg/kg doses of both nanoparticles in PTZ-treated animals elevated TNF-α expression, suggesting a possible negative dose-dependent effect. TAS levels were significantly increased in the PTZ + CBZ-CDs@MOFs 25&#xa0;mg/kg and 50&#xa0;mg/kg groups, implying an antioxidant role for MOF particles. No significant changes were observed in TOS and MDA levels.</p> Conclusions <p>This research underscores the therapeutic promise of nanomaterials in epilepsy management, paving the way for advanced treatments.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neurotherapeutic Potential of Carbamazepine Carbon Nanodot-Functionalized Silver Nanoparticles and MOF-5 in an Experimental Rat Model of Epilepsy

  • 期刊论文

  • 发表日期：

    2025年9月12日

查看全文
  • Adem Tokpinar,
  • Semih Tan,
  • Hasan Ilhan,
  • Emin Kaymak,
  • Muhammet Değermenci,
  • Orhan Baş

摘要

Background

This study investigates the effects of carbamazepine (CBZ) carbon nanodot functionalized silver nanoparticles (CBZ-CD@AgNP) and carbamazepine-loaded metal–organic frameworks (CBZ-CDs@MOFs) on the brain of male rats in an epilepsy model.

Methods

In our study, 70 male Wistar albino rats aged 8–12 weeks were used. Experimental groups Control group, PTZ (Pentylenetetrazole) group, Carbamazepine 25 mg/kg group, Carbamazepine 50 mg/kg group, PTZ + Carbamazepine 25 mg/kg group, PTZ + Carbamazepine 50 mg/kg group, Carbamazepine 25 mg/kg + MOF group, Carbamazepine 50 mg/kg group + MOF group, PTZ + Carbamazepine 25 mg/kg group + MOF group, PTZ + Carbamazepine 50 mg/kg group + MOF group.

Results

Immunohistochemical analysis showed an increase in GRP78 expression in all CBZ-nanoparticle groups, indicating a protective effect. However, 25 mg/kg doses of both nanoparticles in PTZ-treated animals elevated TNF-α expression, suggesting a possible negative dose-dependent effect. TAS levels were significantly increased in the PTZ + CBZ-CDs@MOFs 25 mg/kg and 50 mg/kg groups, implying an antioxidant role for MOF particles. No significant changes were observed in TOS and MDA levels.

Conclusions

This research underscores the therapeutic promise of nanomaterials in epilepsy management, paving the way for advanced treatments.